oral ibuprofen

Phase 2

RRush University Medical Center

oral ibuprofen is one of 7 therapeutic programs targeting Pain Management. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Pain ManagementRecruiting

Symptomatic Irreversible PulpitisCompleted

Pain ManagementPhase 2

Recruiting

Symptomatic Irreversible PulpitisPhase 1

Completed

Competition

Competitive Landscape

8 competitors in Pain Management

#DrugCompanyPhaseTrials

Marcaine

IInnocoll

Phase 3

3 2

Toradol

JJavelin Pharmaceuticals

Phase 2

5 3

Oxycontin

PProtega

Preclinical

9 4

oral ibuprofen

RRush University Medical Center

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Pain Management

NCT07487246

Clinical

Trials by Indication[1]

Symptomatic Irreversible Pulpitis1 trial

Effect of Preoperative Oral Ibuprofen on Anesthetic Efficacy of Inferior Alveolar Nerve Block With Supplemental Buccal and Lingual Infiltrations Using Articaine in Mandibular Molar Teeth With Irreversible Pulpitis: A Randomized Controlled Double-blind Study

Completed·CCairo University·Phase 1·NCT05927922·48 enrolled

Pain Management1 trial

Effects of Paracervical Block With Combined Ketorolac and Lidocaine on Perceived Pain in Osmotic Dilator Placement for Abortion, a Randomized Controlled Trial

Recruiting·RRush University Medical Center·Phase 2·NCT07487246·76 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for oral ibuprofen. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for oral ibuprofen. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Rush University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: RRush University Medical Center

oral ibuprofen

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Symptomatic Irreversible Pulpitis1 trial

Pain Management1 trial

References

Drug Info

Quick Facts

Related News